Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Tasly Pharmaceutical Group Co., Ltd
  6. News
  7. Summary
    600535   CNE000001C81

TASLY PHARMACEUTICAL GROUP CO., LTD

(600535)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-11-29
11.78 CNY   -0.59%
11/17Mauna Kea Technologies reports its Financial Results for the First Half of 2022
AQ
11/07Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Venture in China
CI
10/25Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022

04/25/2022 | 03:38am EST

Tasly Pharmaceutical Group Co., Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 1,869.32 million compared to CNY 1,764.09 million a year ago. Revenue was CNY 1,869.32 million compared to CNY 1,764.09 million a year ago. Net loss was CNY 557.19 million compared to net income of CNY 322.96 million a year ago. Basic loss per share from continuing operations was CNY 0.3719 compared to basic earnings per share from continuing operations of CNY 0.2149 a year ago. Diluted loss per share from continuing operations was CNY 0.3719 compared to diluted earnings per share from continuing operations of CNY 0.2149 a year ago.


ę S&P Capital IQ 2022
All news about TASLY PHARMACEUTICAL GROUP CO., LTD
11/17Mauna Kea Technologies reports its Financial Results for the First Half of 2022
AQ
11/07Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Ve..
CI
10/25Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended ..
CI
09/30Tasly Pharmaceutical Wins Nod For Clinical Trial of Psoriasis Drug
MT
08/19Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended Ju..
CI
08/19Tasly Pharmaceutical Group Scraps Plan to Spin Off BioPharm Unit for Listing
CI
07/12Transcript : Mauna Kea Technologies SA, Tasly Pharmaceutical Group Co., Ltd -..
CI
07/11Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing A..
CI
04/25Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ende..
CI
03/30Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended De..
CI
More news
Financials
Sales 2022 8 464 M 1 195 M 1 195 M
Net income 2022 514 M 72,5 M 72,5 M
Net cash 2022 819 M 116 M 116 M
P/E ratio 2022 34,6x
Yield 2022 4,16%
Capitalization 17 504 M 2 471 M 2 471 M
EV / Sales 2022 1,97x
EV / Sales 2023 1,86x
Nbr of Employees 9 437
Free-Float 50,7%
Chart TASLY PHARMACEUTICAL GROUP CO., LTD
Duration : Period :
Tasly Pharmaceutical Group Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TASLY PHARMACEUTICAL GROUP CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 11,78 CNY
Average target price 10,18 CNY
Spread / Average Target -13,6%
EPS Revisions
Managers and Directors
Jing Su Director
Jie Wei Chief Financial Officer
Kai Jing Yan Chairman
Zheng Liang Ye Chairman-Supervisory Board
Ai Jian Wang Independent Director